Li-Ping Zhao1,
Lu-Jia Zou1,
Jing-Hui He2 
For correspondence:- Jing-Hui He Email: jinghuehe@yahoo.com Tel:+862152889999
Accepted: 26 September 2019 Published: 31 October 2019
Citation: Zhao L, Zou L, He J. Postoperative vomiting/nausea in Chinese patients undergoing bariatric surgery. Trop J Pharm Res 2019; 18(10):2211-2217 doi: 10.4314/tjpr.v18i10.30
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To assess the incidence of post-operative vomiting/nausea (PVN), as well as usage and effectiveness of PVN prophylaxis in Chinese patients receiving bariatric surgery.
Methods: This prospective observational study included 82 patients subjected to bariatric surgery using total intravenous (IV) anesthesia. Patients were given PVN prophylactic treatment as per the local practice depending on Apfel et al criterion for simplified risk score useful for PVN prediction. Post-surgery, the patients were evaluated at 2, 4, 6, 24, 48 and 72 h using a questionnaire. Univariate analysis of risk factors associated with PVN was carried conducted with Pearson’s Chi-squared test for category variables and Mann–Whitney–Wilcoxon test for a continuous variable.
Results: About 69 % of the patients developed PVN within 24 h post-surgery, and the risk increased with increase in the number of PVN risk factors. Significant contrasts were seen with respect to PVN, with higher occurrence in females (81.36 %), when compared to males (39.13 %) within the first 24 h (p < 0.05). Two patients got sub-optimum PVN prophylactic therapy as per guidelines, 19 patients had optimum therapy, while 61 patients had supra-optimum therapy. Moreover, 63.94 % of patients who obtained supra-optimum PVN prophylactic therapy experienced PVN within 24 h post-surgery, while 84.21 % of patients with optimum PVN prophylactic therapy experienced PVN within the same period (p < 0.05). Overall, 35.37 % of patients experienced serious nausea 24 h post-surgery.
Conclusion: PVN incidence is high, notwithstanding the fact that almost all the patients received optimum or supra-optimum prophylactic therapy. These findings raise dubiety regarding the viability and significance of using risk-based PVN prophylactic therapy in patients under bariatric surgery. Thus, further research is needed in this regard.
Archives
News Updates
Fulltext in PDF